Biora Therapeutics, Inc. (PROG) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Loading...

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

How to use About us Blog

|

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

How to use About us Blog

Follow our journey and product updates

Product

Research a topic Stock screener Find companies Search for securities Load an existing portfolio Backtest

Learn

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices Build investment strategies with crypto

Company

How to use About us Blog

Team Research

Save modules, company pages, indices, or research results to your research for later reference.

Biora Therapeutics, Inc. (PROG)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Company performance

Add to research

Current Price

as of Feb 07, 2025

$0.16

P/E Ratio

N/A

Market Cap

$719.11K

Description

Add to research

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

Metrics

Add to research

Overview

HQSan Diego, CA
SectorHealth Services
IndustryMedical/Nursing Services
TickerPROG
Price$0.159+6.35%

Trading Information

Market cap$0.72M
Float96.63%
Average Daily Volume (1m)28,037
Average Daily Volume (3m)120,745
EPS-$10.87

Company

Revenue$0.89M
Rev growth (1yr)N/A
Net income-$22.22M
Gross margin-246.88%
EBITDA margin-50,362.50%
EBITDA-$16.12M

EV$54.77M
EV/Revenue61.40
P/EN/A
P/S0.65
P/BN/A
Debt/EquityN/A

Documents

Add to research

Factset Street Account

StreetAccount Earnings Call Q&A Summary: Biora Therapeutics Q3 (2023-11-22T19:21:21Z)

Biora Therapeutics to submit updated IND application for BT-600 ($2.44, 0.00) (2023-10-23T21:32:54Z)

Biora Therapeutics submits updated IND Application for BT-600 ($2.02, 0.00) (2023-10-30T20:16:08Z)

Biora Therapeutics reports Q3 EPS ($4.89) vs year-ago ($0.68) ($1.34, 0.00) (2023-11-13T21:13:01Z)

Biora Therapeutics presents data on the BioJet systemic oral delivery platform in short oral discussion at 59th European Association for the Study of Diabetes ($2.18, 0.00) (2023-10-05T12:07:20Z)

Biora Therapeutics announces new patent for its NaviCap targeted oral delivery platform ($1.19, 0.00) (2023-12-19T13:06:36Z)

Biora Therapeutics announces FDA clearance of IND application for drug/device combination BT-600 targeting treatment of ulcerative colitis ($1.24, 0.00) (2023-11-30T21:49:42Z)

Biora Therapeutics announces convertible note exchange agreement ($1.36, 0.00) (2023-12-18T13:11:49Z)

Earnings Calls

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report 2021Q4

Earnings Report (2022-03-28)

Factset

Factset Business Description

Ask a question

New feature

Thematic Research

View all of your research in one place. Toggle open the floating actions menu and click Open research sidebar to view your saved research for the current page.